Both in vivo FSH depletion and follicular exposure to Gonadotrophinreleasing hormone analogues in vitro are not effective to prevent follicular depletion during chemotherapy in mice

Molecular Human Reproduction

Volumn 24, Issue 4, 2017, Pages 221-232

  Horicks, F ^a   Van Den Steen, G ^a   Gervy, C ^b   Clarke, H J ^c   Demeestere, I ^a  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^b ERASME HOSPITAL   (Belgium)

^c RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

Apoptosis; Cyclophosphamide; Fertility preservation; FSH; GnRH analogues

Indexed keywords

CHORIONIC GONADOTROPIN; CYCLIC AMP; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR; FOLLITROPIN; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; GONADORELIN DERIVATIVE; GONADORELIN RECEPTOR; PERFOSFAMIDE; SERIC GONADOTROPIN; GONADORELIN;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTRAL FOLLICLE; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CELL ISOLATION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DEPLETION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; FEMALE; FERTILITY PRESERVATION; FOLLITROPIN RELEASE; GONADOTROPIN RELEASE; GRANULOSA CELL; HORMONE INHIBITION; HYPOPHYSIS GONAD SYSTEM; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NEWBORN; NONHUMAN; OOCYTE MATURATION; OVARIAN RESERVE; OVARY FOLLICLE; OVARY FOLLICLE DEVELOPMENT; OVARY INSUFFICIENCY; PREPUBERTY; PRIORITY JOURNAL; PROTEIN EXPRESSION; STEROIDOGENESIS; ANIMAL; METABOLISM; PHYSIOLOGY;

ANIMALS; APOPTOSIS; CYCLOPHOSPHAMIDE; FEMALE; FOLLICLE STIMULATING HORMONE; GONADOTROPIN-RELEASING HORMONE; MICE; OVARIAN FOLLICLE;

EID: 85050620011     PISSN: 13609947     EISSN: 14602407     Source Type: Journal    
DOI: 10.1093/molehr/gay005     Document Type: Article

References (66)

1. Arora KK, Chung HO, Catt KJ. Influence of a species-specific extracellular amino acid on expression and function of the human gonadotropinreleasing hormone receptor. Mol Endocrinol 1999;13:890-896
2. Ataya KM, McKanna JA, Weintraub AM, Clark MR, LeMaire WJ. A luteinizing hormone-releasing hormone agonist for the prevention of chemotherapy-induced ovarian follicular loss in rats. Cancer Res 1985; 45:3651-3656
3. Ataya K, Rao LV, Lawrence E, Kimmel R. Luteinizing hormone-releasing hormone agonist inhibits cyclophosphamide-induced ovarian follicular depletion in rhesus monkeys. Biol Reprod 1995;52:365-372
4. Bauer-Dantoin AC, Jameson JL. Gonadotropin-releasing hormone receptor messenger ribonucleic acid expression in the ovary during the rat estrous cycle. Endocrinology 1995;136:4432-4438
5. Behringer K, Wildt L, Mueller H, Mattle V, Ganitis P, van den Hoonaard B, Ott HW, Hofer S, Pluetschow A, Diehl V et al. No protection of the ovarian follicle pool with the use of GnRH-analogues or oral contraceptives in young women treated with escalated BEACOPP for advancedstage Hodgkin lymphoma. Final results of a phase II trial from the German Hodgkin Study Group. Ann Oncol 2010;21:2052-2060
6. Bildik G, Akin N, Senbabaoglu F, Sahin GN, Karahuseyinoglu S, Ince U, Taskiran C, Selek U, Yakin K, Guzel Y et al. GnRH agonist leuprolide acetate does not confer any protection against ovarian damage induced by chemotherapy and radiation in vitro. Hum Reprod 2015;30:2912-2925
7. Birnbaumer L, Shahabi N, Rivier J, Vale W. Evidence for a physiological role of gonadotropin-releasing hormone (GnRH) or GnRH-like material in the ovary. Endocrinology 1985;116:1367-1370
8. Blumenfeld Z. How to preserve fertility in young women exposed to chemotherapy? The role of GnRH agonist cotreatment in addition to cryopreservation of embrya, oocytes, or ovaries. Oncologist 2007;12: 1044-1054
9. Bokser L, Szende B, Schally AV. Protective effects of D-Trp6-luteinising hormone-releasing hormone microcapsules against cyclophosphamideinduced gonadotoxicity in female rats. Br J Cancer 1990;61:861-865
10. Brooker G, Harper JF, Terasaki WL, Moylan RD. Radioimmunoassay of cyclic AMP and cyclic GMP. Adv Cyclic Nucleotide Res 1979;10:1-33
11. Chapman RM, Sutcliffe SB. Protection of ovarian function by oral contraceptives in women receiving chemotherapy for Hodgkin's disease. Blood 1981;58:849-851
12. Cheung LW, Wong AS. Gonadotropin-releasing hormone: GnRH receptor signaling in extrapituitary tissues. FEBS J 2008;275:5479-5495
13. Choi KC, Auersperg N, Leung PC. Expression and antiproliferative effect of a second form of gonadotropin-releasing hormone in normal and neoplastic ovarian surface epithelial cells. J Clin Endocrinol Metab 2001; 86:5075-5078
14. Choi JH, Gilks CB, Auersperg N, Leung PC. Immunolocalization of gonadotropin-releasing hormone (GnRH)-I, GnRH-II, and type I GnRH receptor during follicular development in the human ovary. J Clin Endocrinol Metab 2006;91:4562-4570
15. Clayton RN, Harwood JP, Catt KJ. Gonadotropin-releasing hormone analogue binds to luteal cells and inhibits progesterone production. Nature 1979;282:90-92
16. Danforth DR, Arbogast LK, Friedman CI. Acute depletion of murine primordial follicle reserve by gonadotropin-releasing hormone antagonists. Fertil Steril 2005;83:1333-1338
17. Demeestere I, Brice P, Peccatori FA, Kentos A, Dupuis J, Zachee P, Casasnovas O, Van Den Neste E, Dechene J, De Maertelaer V et al. No Evidence for the benefit of gonadotropin-releasing hormone agonist in preserving ovarian function and fertility in lymphoma survivors treated with chemotherapy: final long-term report of a prospective randomized trial. J Clin Oncol 2016;34:2568-2574
18. Demeestere I, Gervy C, Centner J, Devreker F, Englert Y, Delbaere A. Effect of insulin-like growth factor-I during preantral follicular culture on steroidogenesis, in vitro oocyte maturation, and embryo development in mice. Biol Reprod 2004;70:1664-1669
19. Demeestere I, Streiff AK, Suzuki J, Al-Khabouri S, Mahrous E, Tan SL, Clarke HJ. Follicle-stimulating hormone accelerates mouse oocyte development in vivo. Biol Reprod 2012;87:1-11
20. Desmeules P, Devine PJ. Characterizing the ovotoxicity of cyclophosphamide metabolites on cultured mouse ovaries. Toxicol Sci 2006;90:500-509
21. Detti L, Uhlmann RA, Zhang J, Diamond MP, Saed GM, Fletcher NM, Lu M, Williams LJ. Goserelin fosters bone elongation but does not prevent ovarian damage in cyclophosphamide-treated prepubertal mice. Fertil Steril 2014;101:1157-1164 e1151
22. Devine PJ, Perreault SD, Luderer U. Roles of reactive oxygen species and antioxidants in ovarian toxicity. Biol Reprod 2012;86:27
23. Devine PJ, Sipes IG, Hoyer PB. Initiation of delayed ovotoxicity by in vitro and in vivo exposures of rat ovaries to 4-vinylcyclohexene diepoxide. Reprod Toxicol 2004;19:71-77
24. D'Occhio MJ, Cremonesi F, Trigg TE, Aspden WJ, Baruselli PS. Acute follicular response to FSH in heifers downregulated long term with a GnRH agonist and with suppressed ovarian follicular growth. Theriogenology 2013;80:999-1005
25. Ezoe K, Murata N, Yabuuchi A, Okuno T, Kobayashi T, Kato O, Kato K. Long-term adverse effects of cyclophosphamide on follicular growth and angiogenesis in mouse ovaries. Reprod Biol 2014;14:238-242
26. Glode LM, Robinson J, Gould SF. Protection from cyclophosphamideinduced testicular damage with an analogue of gonadotropin-releasing hormone. Lancet 1981;1:1132-1134
27. Gougeon A. Regulation of ovarian follicular development in primates: facts and hypotheses. Endocrine Rev 1996;17:121-155
28. Hong IS, Klausen C, Cheung AP, Leung PC. Gonadotropin-releasing hormone-I or-II interacts with IGF-I/Akt but not connexin 43 in human granulosa cell apoptosis. J Clin Endocrinol Metab 2012;97:525-534
29. Horicks F, Van Den Steen G, Houben S, Englert Y, Demeestere I. Folliculogenesis is not fully inhibited during GnRH analogues treatment in mice challenging their efficiency to preserve the ovarian reserve during chemotherapy in this model. PloS one 2015;10:e0137164
30. Hsueh MJ, Adashi EY, Tucker E, Valk C, Ling NC. Relative potencies of gonadotropin-releasing hormone agonists and antagonists on ovarian and pituitary functions. Endocrinol 1983;112:689-695
31. Huang YH, Zhao XJ, Zhang QH, Xin XY. The GnRH antagonist reduces chemotherapy-induced ovarian damage in rats by suppressing the apoptosis. Gynecol Oncol 2009;112:409-414
32. Janssens RM, Brus L, Cahill DJ, Huirne JA, Schoemaker J, Lambalk CB. Direct ovarian effects and safety aspects of GnRH agonists and antagonists. Human Reprod Update 2000;6:505-518
33. Kitajima Y, Endo T, Nagasawa K, Manase K, Honnma H, Baba T, Hayashi T, Chiba H, Sawada N, Saito T. Hyperstimulation and a gonadotropinreleasing hormone agonist modulate ovarian vascular permeability by altering expression of the tight junction protein claudin-5. Endocrinology 2006;147:694-699
34. Lambertini M, Ceppi M, Poggio F, Peccatori FA, Azim HA Jr., Ugolini D, Pronzato P, Loibl S, Moore HC, Partridge AH et al. Ovarian suppression using luteinizing hormone-releasing hormone agonists during chemotherapy to preserve ovarian function and fertility of breast cancer patients: a metaanalysis of randomized studies. Ann Oncol 2015;26:2408-2419
35. Lemos CN, Reis FM, Pena GN, Silveira LC, Camargos AF. Assessment of fertility protection and ovarian reserve with GnRH antagonist in rats undergoing chemotherapy with cyclophosphamide. Reprod Biol Endocrinol 2010;8:51
36. Leung PC, Cheng CK, Zhu XM. Multi-factorial role of GnRH-I and GnRHII in the human ovary. Mol Cell Endocrinol 2003;202:145-153
37. Li Q, Szatmary P, Liu Y, Ding Z, Zhou J, Sun Y, Luo F, Wang Y, Zhu J. Orthotopic transplantation of cryopreserved mouse ovaries and gonadotrophin releasing hormone analogues in the restoration of function following chemotherapy-induced ovarian damage. PLoS One 2015; 10:e0120736
38. Li F, Turan V, Lierman S, Cuvelier C, De Sutter P, Oktay K. Sphingosine-1-phosphate prevents chemotherapy-induced human primordial follicle death. Human Reprod 2014;29:107-113
39. Luderer U, Kavanagh TJ, White CC, Faustman EM. Gonadotropin regulation of glutathione synthesis in the rat ovary. Reprod Toxicol 2001;15:495-504
40. Maggi R, Cariboni AM, Marelli MM, Moretti RM, Andre V, Marzagalli M, Limonta P. GnRH and GnRH receptors in the pathophysiology of the human female reproductive system. Human Reprod Update 2016;22: 358-381
41. Matikainen T, Ding YQ, Vergara M, Huhtaniemi I, Couzinet B, Schaison G. Differing responses of plasma bioactive and immunoreactive folliclestimulating hormone and luteinizing hormone to gonadotropin-releasing hormone antagonist and agonist treatments in postmenopausal women. J Clin Endocrinol Metab 1992;75:820-825
42. Matsuo G, Ushijima K, Shinagawa A, Takahashi S, Fujiyoshi N, Takemoto S, Terada A, Fukui A, Kamura T. GnRH agonist acts as ovarian protection in chemotherapy induced gonadotoxicity: an experiment using a rat model. Kurume Med J 2007;54:25-29
43. Meirow D, Assad G, Dor J, Rabinovici J. The GnRH antagonist cetrorelix reduces cyclophosphamide-induced ovarian follicular destruction in mice. Human Reprod 2004;19:1294-1299
44. Millar RP, Pawson AJ, Morgan K, Rissman EF, Lu ZL. Diversity of actions of GnRHs mediated by ligand-induced selective signaling. Front Neuroendocrinol 2008;29:17-35
45. Montz FJ, Wolff AJ, Gambone JC. Gonadal protection and fecundity rates in cyclophosphamide-treated rats. Cancer Res 1991;51:2124-2126
46. Moore HC, Unger JM, Phillips KA, Boyle F, Hitre E, Porter D, Francis PA, Goldstein LJ, Gomez HL, Vallejos CS et al. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. New Engl J Med 2015; 372:923-932
47. Morgan S, Lopes F, Gourley C, Anderson RA, Spears N. Cisplatin and doxorubicin induce distinct mechanisms of ovarian follicle loss; imatinib provides selective protection only against cisplatin. PloS one 2013;8: e70117
48. Munoz M, Santaballa A, Segui MA, Beato C, de la Cruz S, Espinosa J, Fonseca PJ, Perez J, Quintanar T, Blasco A. SEOM Clinical Guideline of fertility preservation and reproduction in cancer patients (2016). Clin Transl Oncol 2016;18:1229-1236
49. Oktay K, Briggs D, Gosden RG. Ontogeny of follicle-stimulating hormone receptor gene expression in isolated human ovarian follicles. J Clin Endocrinol Metab 1997;82:3748-3751
50. Oktay K, Sonmezer M, Oktem O, Fox K, Emons G, Bang H. Absence of conclusive evidence for the safety and efficacy of gonadotropin-releasing hormone analogue treatment in protecting against chemotherapyinduced gonadal injury. Oncologist 2007;12:1055-1066
51. Oktem O, Oktay K. A novel ovarian xenografting model to characterize the impact of chemotherapy agents on human primordial follicle reserve. Cancer Res 2007;67:10159-10162
52. Plowchalk DR, Mattison DR. Reproductive toxicity of cyclophosphamide in the C57BL/6N mouse: 1. Effects on ovarian structure and function. Reprod Toxicol 1992;6:411-421
53. Roness H, Gavish Z, Cohen Y, Meirow D. Ovarian follicle burnout: a universal phenomenon? Cell Cycle 2013;12:3245-3246
54. Roness H, Kashi O, Meirow D. Prevention of chemotherapy-induced ovarian damage. Fertil Steril 2016;105:20-29
55. Rossi V, Lispi M, Longobardi S, Mattei M, Rella FD, Salustri A, De Felici M, Klinger FG. LH prevents cisplatin-induced apoptosis in oocytes and preserves female fertility in mouse. Cell Death Differ 2017;24:72-82
56. Roti Roti EC, Leisman SK, Abbott DH, Salih SM. Acute doxorubicin insult in the mouse ovary is cell-and follicle-type dependent. PLoS One 2012;7: e42293
57. Sealfon SC, Weinstein H, Millar RP. Molecular mechanisms of ligand interaction with the gonadotropin-releasing hormone receptor. Endocr Rev 1997;18:180-205
58. Takekida S, Matsuo H, Maruo T. GnRH agonist action on granulosa cells at varying follicular stages. Mol Cell Endocrinol 2003;202:155-164
59. Tan SJ, Yeh YC, Shang WJ, Wu GJ, Liu JY, Chen CH. Protective effect of a gonadotropin-releasing hormone analogue on chemotherapeutic agentinduced ovarian gonadotoxicity: a mouse model. Eur J Obstet Gynecol Reprod Biol 2010;149:182-185
60. Torrealday S, Lalioti MD, Guzeloglu-Kayisli O, Seli E. Characterization of the gonadotropin releasing hormone receptor (GnRHR) expression and activity in the female mouse ovary. Endocrinology 2013;154:3877-3887
61. Tsai-Turton M, Luong BT, Tan Y, Luderer U. Cyclophosphamide-induced apoptosis in COV434 human granulosa cells involves oxidative stress and glutathione depletion. Toxicol Sci 2007;98:216-230
62. Uemura T, Namiki T, Kimura A, Yanagisawa T, Minaguchi H. Direct effects of gonadotropin-releasing hormone on the ovary in rats and humans. Horm Res 1994;41:7-13
63. Wang Y, Ho CC, Bang E, Rejon CA, Libasci V, Pertchenko P, Hebert TE, Bernard DJ. Bone morphogenetic protein 2 stimulates noncanonical SMAD2/3 signaling via the BMP type 1A receptor in gonadotropelike cells: implications for FSH synthesis. Endocrinology 2014;155: 1970-1981
64. Whitelaw PF, Eidne KA, Sellar R, Smyth CD, Hillier SG. Gonadotropinreleasing hormone receptor messenger ribonucleic acid expression in rat ovary. Endocrinology 1995;136:172-179
65. Yang Q, Allard P, Huang M, Zhang W, Clarke HJ. Proteasomal activity is required to initiate and to sustain translational activation of messenger RNA encoding the stem-loop-binding protein during meiotic maturation in mice. Biol Reprod 2010;82:123-131
66. Zhao XJ, Huang YH, Yu YC, Xin XY. GnRH antagonist cetrorelix inhibits mitochondria-dependent apoptosis triggered by chemotherapy in granulosa cells of rats. Gynecol Oncol 2010;118:69-75